pre-IPO PHARMA

COMPANY OVERVIEW

AgilVax’s lead product, AX09, produces antibodies that specifically inhibit the function of xCT, a protein that is overexpressed on numerous tumor types including metastatic breast, colorectal, lung, pancreatic, hepatocellular cancers and glioblastoma. * By inhibiting the function of xCT, AX09, has the potential to enhance the effectiveness of current therapies, reduce metastatic spread, and make a dramatic improvement in patient survival.


LOCATION

  • Albuquerque, NM, USA
  • Houston, TX, USA
  • El Paso, TX, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.agilvax.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    hunt-holdings sun-mountain-capital


    PRESS RELEASES


    Aug 18, 2020

    AgilVax Progress Triggers $1.2 Million SBIR Fast-Track Grant to Advance Antibody-Based Therapy


    Jan 16, 2020

    AgilVax Announces Expansion of Series A-1 Financing


    Nov 18, 2019

    AgilVax to Present Positive Preclinical Data for Monoclonal Antibody Targeting xCT at the American Association for Cancer Research’s Tumor Immunology and Immunotherapy Conference


    Nov 7, 2019

    AgilVax to Present at the 2019 NYC Oncology Investor Conference


    Jul 25, 2019

    AgilVax Appoints Dr. Joseph Patti as Chief Executive Officer


    For More Press Releases


    Google Analytics Alternative